February 16, 2026 |
How can pharma teams scale AI safely across channels? In this session, Ed Hart and Nicolas Barcza explore why strong Design Systems are the foundation for making AI operational, compliant and scalable.

AI is high on the agenda for pharma teams, but adding it into complex, highly regulated environments isn’t straightforward. In this session from the NEXT CX & AI Conference, Ed Hart, Head of Design at Graphite Digital, and independent pharma CX expert Nicolas Barcza explore why scaling AI successfully depends less on the technology itself and more on the Design System that governs it.
They unpack how structured, machine-readable Design Systems can embed brand, compliance and market logic directly into digital workflows — allowing AI to accelerate asset creation, reduce review cycles and support consistent omnichannel delivery. The result isn’t just operational efficiency, but safer, more scalable digital experiences for HCPs and patients.
This content was provided by Graphite Digital
Company Details
Latest Content from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising…
Design Systems aren’t new, but the potential to utilise them to improve the way in which teams produce digital products is still untapped for many in the pharmaceutical and healthcare…
Six months on from releasing our research report, we reflect on the themes raised and offer practical advice on how contradictions can be overcome to enable digital success in pharma…
Demonstrating the value of UX research in pharma and healthcare can be difficult. Here, Graphite’s Senior Clinical UX Researcher, Jack Burton, explains the importance of user research within the digital…
We take a look at why it can take pharma businesses so long to get their digital products into the hands of patients or HCPs, and what can be done…
New research, based on the views of 450 pharma professionals, reveals contradictions in how pharma organisations are approaching their digital products and strategies.
